Back to the main directory
EarningsReview / Equity
- Itaú BBA on Brazil Healthcare: Glimmers of Hope – Healthcare 1Q23 Earnings Wrap-Up by Itau
- Strong organic growth, fully valued by BNP Paribas Exane
- Asset Optimisation Options by BNP Paribas Exane
- Holidays; celebrate by BNP Paribas Exane
- GVS - GOOD MARGIN IMPROVEMENT DESPITE THE SEVERE DESTOCKING by Equita Sim
- Innovatec SpA - Moins de B2C by MidCap Partners
- Leroey Seafood Group - Hold (Buy/NOK 65): Falling short, once again by Nordea
- Melrose Industries - The stars are aligned by Edison Investment Research
- Immix Biopharma - A quarter focusing on a CAR-T strategy by Edison Investment Research
- INVEST SECURITIES - VALBIOTIS : REVERSE-IT : Converted try- BUY, TP €12,3 vs €10,3) by Invest Securities
- Boots on the ground by BNP Paribas Exane
- Dowlais Group - Positive start to the year by Edison Investment Research
- 分众传媒（002027 CH） by HSBC
- GRUPO SANJOSE: RDOS. 1T’23 (ANÁLISIS BANCO SABADELL) by Sabadell
- The Pebble Group - H123 trading ahead of prior year by Edison Investment Research
- BlackRock Sustainable American Income Trust - Unique value and ESG strategy by Edison Investment Research
- Hiring advisers, improving flows by BNP Paribas Exane
- The Ultimate Show-Me by BNP Paribas Exane
- Margins, thus far, more stable than comps by BNP Paribas Exane
- An untimely commercial break by BNP Paribas Exane
- Camurus (Buy, TP: SEK320.00) - US approval for Brixadi by DnB Markets
- Norva24 (Buy, TP: SEK42.00) - Solid start to 2023 by DnB Markets
- Ryanair (RYA ID) by HSBC
- Netcompany - 1 June CMD – focus on medium-term ambitions by Danske Bank Equity Research
- Weak Q1 FCF to Improve Through Remainder of 2023 by BNP Paribas Exane